These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29734173)

  • 41. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
    Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
    Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
    Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
    Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients.
    Torino C; Pizzini P; Cutrupi S; Postorino M; Tripepi G; Mallamaci F; Reiser J; Zoccali C;
    Kidney Int Rep; 2018 Sep; 3(5):1100-1109. PubMed ID: 30197976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
    Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
    Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. suPAR: A New Biomarker for Cardiovascular Disease?
    Hodges GW; Bang CN; Wachtell K; Eugen-Olsen J; Jeppesen JL
    Can J Cardiol; 2015 Oct; 31(10):1293-302. PubMed ID: 26118447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.
    Ghasemzedah N; Hayek SS; Ko YA; Eapen DJ; Patel RS; Manocha P; Al Kassem H; Khayata M; Veledar E; Kremastinos D; Thorball CW; Pielak T; Sikora S; Zafari AM; Lerakis S; Sperling L; Vaccarino V; Epstein SE; Quyyumi AA
    Circ Cardiovasc Qual Outcomes; 2017 Mar; 10(3):. PubMed ID: 28280039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
    Sommerer C; Zeier M; Morath C; Reiser J; Scharnagl H; Stojakovic T; Delgado GE; März W; Kleber ME
    Sci Rep; 2019 Jan; 9(1):475. PubMed ID: 30679668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
    Höbaus C; Ursli M; Yussef SM; Wrba T; Koppensteiner R; Schernthaner GH
    Vasc Med; 2021 Feb; 26(1):11-17. PubMed ID: 33448911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between the triglyceride-glucose index and coronary artery calcification in asymptomatic, non-diabetic patients undergoing maintenance hemodialysis.
    Ding H; Zhu J; Tian Y; Xu L; Song L; Shi Y; Mu D; Chen R; Liu H; Liu B
    Ren Fail; 2023 Dec; 45(1):2200849. PubMed ID: 37133817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
    Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
    JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery?
    Schultz-Swarthfigure CT; McCall P; Docking R; Galley HF; Shelley B
    Interact Cardiovasc Thorac Surg; 2021 Jan; 32(2):236-243. PubMed ID: 33236082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
    Gozdzik W; Adamik B; Gozdzik A; Rachwalik M; Kustrzycki W; Kübler A
    PLoS One; 2014; 9(6):e98923. PubMed ID: 24911522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
    Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
    Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time.
    Enocsson H; Lukic T; Ziegelasch M; Kastbom A
    Transl Res; 2021 Jun; 232():142-149. PubMed ID: 33582243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Eur J Intern Med; 2019 Jun; 64():72-75. PubMed ID: 31060962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.